Overview

Bioequivalence of Two Formulations of Meropenem Intravenous Injection

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
A randomized, single-dose, two-way crossover study to evaluate bioequivalence of two formulations of meropenem (meropenem intravenous injection 0.5 g) after intravenous infusion in healthy volunteers.
Phase:
Phase 4
Details
Lead Sponsor:
Yung Shin Pharm. Ind. Co., Ltd.
Treatments:
Meropenem